- The stock of Quest Diagnostics (DGX, Financial) experienced a notable 8% increase following stronger-than-expected Q1 earnings.
- The company has updated its 2025 EPS forecast to $8.62-$8.87 and improved its cash flow expectations to $1.5 billion.
- Analyst consensus shows an "Outperform" rating and a projected average price target of $180.78 for DGX.
Quest Diagnostics (DGX), a prominent player in the medical diagnostics field, saw its shares rise by about 8% after announcing impressive first-quarter earnings results. The company has boosted its 2025 earnings per share guidance to a range of $8.62-$8.87, up from the previous forecast of $8.34-$8.59. Furthermore, cash flow expectations have been improved to $1.5 billion, though net revenue projections remain steady between $10.7 billion and $10.85 billion.
Wall Street Analysts’ Projections
Wall Street analysts have issued one-year price targets for Quest Diagnostics Inc (DGX, Financial), with an average target price calculated at $180.78. Price estimates range from a high of $198.00 to a low of $160.00, suggesting a potential upside of 3.87% from the current trading price of $174.04. For more detailed projections, please visit the Quest Diagnostics Inc (DGX) Forecast page.
Brokerage Recommendations
According to the consensus from 20 brokerage firms, Quest Diagnostics Inc (DGX, Financial) holds an average brokerage recommendation of 2.2, which aligns with an "Outperform" status. This rating is derived from a scale where 1 indicates a Strong Buy and 5 designates a Sell.
GF Value Insights
In terms of valuation, GuruFocus estimates the GF Value for Quest Diagnostics Inc (DGX, Financial) over the next year to be $156.78, implying a potential downside of 9.92% from the current stock price of $174.04. GF Value represents GuruFocus' fair value assessment, calculated using historical trading multiples, past business growth, and forward-looking performance estimates. For a comprehensive overview, visit the Quest Diagnostics Inc (DGX) Summary page.
